The diagnosis and treatment of human diseases and the development of new drugs increasingly rely on our ability to determine patient genotypes using accurate and sensitive pharmacogenomic tests. Many PCR and next-generation sequencing (NGS) based assay platforms are currently available.
However, the type of DNA sequence variants, the number of targets, and the sensitivity requirements are highly diverse in different studies. Here Dr. Peter Zhang describes the design, performance, and regulatory considerations of several assay platforms that are accurate, high throughput, cost-effective and customizable. These platforms provide high-quality pharmacogenomic data ideally suited to meet the needs of individual studies.
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
In this eBook, we navigate the landscape of biomarker discovery through genomic profiling, exploring technologies, methods, and applications. We hope this collection of articles creates an appreciation for the wide scope of using sequencing assays for biomarker discovery, drug development, and beyond.
Critical reagents – the key components used in LBA – are central to ensuring the consistency and reliability of the assay and can often slow the progress of LBA due to limited availability. In this panel discussion, we examine the current scope of LBAs, the advantages and limitations including matrix interference, as well as the solutions for overcoming these. Additionally, we explore the platforms currently used and the key factors to consider when choosing a platform. Finally, we will highlight key areas for progression.
In this poster, we validate ultra-high sensitive SIMOA assays for the successful quantitation of neurofilament light chain (NF-L) and glial fibrillary acidic protein (GFAP).